Acorda R&D Day Explores Pipeline Opportunities
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Acorda Therapeutics highlighted the other indications it has in the works for its MS drug Ampyra, as well as several early-stage compounds in other neurological indications.